Clinical studies of SGK1 inhibition
Advancing research in heart failure with reduced ejection fraction (HFrEF) and Long QT Syndrome, powered by patients and clinical investigators.
Enrolling soon
Australia
ASPIRE-HF
HFrEF
Phase 2a
Evaluating investigational THRV-1268 in adults with heart failure with reduced ejection fraction (HFrEF) and QTc prolongation who remain at high risk of arrhythmias and worsening heart failure despite current therapies. The clinical study looks at safety and effects on heart rhythm, remodeling and heart failure biomarkers.
Now enrolling
Wave II
United States
LQT2 and LQT3
Phase 2/3
Evaluating investigational THRV-1268 in participants aged 15 and older with Long QT Syndrome Type 2 or Type 3 (LQT2 and LQT3) and a prolonged QTc greater than 480 ms. The clinical study looks at safety and effects on the QTc interval.
Enrollment complete
myQTwave
LQT2 and LQT3
United States (remote)
Observational
Observational study capturing the lived experience and symptom burden of people with Long QT Syndrome Types 2 and 3. Enrollment is complete, with initial results to be presented at AHA Scientific Sessions 2026.
Completed studies
Wave I (Parts 1 and 2): LQT-1213
Completed
Phase 1 studies of THRV-1268
Completed
What to expect if you join a study
Talk to your doctor
Ask whether a study could be right for you.
Screening
A study coordinator guides you through an evaluation to check your eligibility.
It's your choice
Participation is voluntary. You can withdraw from the study at any time.
The safety and efficacy of THRV-1268 have not been established. THRV-1268 is investigational; these research programs do not establish a treatment benefit. THRV-1268 has not been approved for commercial use by any regulatory authority (e.g., the FDA in the United States, Health Canada in Canada, or the TGA in Australia).